The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: The M. D. Anderson Cancer Center evidence-based approach

Cancer

Volumn 101, Issue 7, 2004, Pages 1482-1489

  Morandi, Paolo ^a,b   Rouzier, Roman ^a,c   Altundag, Kadri ^a,d   Buzdar, Aman U ^a   Theriault, Richard L ^a   Hortobagyi, Gabriel ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SAN BORTOLO HOSPITAL   (Italy)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Adjuvant therapy; Aromatase inhibitors; Breast carcinoma; Hormone receptor positive

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; HORMONE RECEPTOR; LETROZOLE; PLACEBO; TAMOXIFEN;

ACNE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FRACTURE; HOT FLUSH; HUMAN; HYPERTRICHOSIS; MEDLINE; MUSCULOSKELETAL DISEASE; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; VISUAL DISORDER;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; POSTMENOPAUSE; PROSPECTIVE STUDIES; TAMOXIFEN; TRIAZOLES;

EID: 4844222029     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20522     Document Type: Review

References (37)

1. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001;93:684-690.
2. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998;351:1451-1467.
3. Love RR, Barden HS, Mazess RB, et al. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med. 1994;154:2585-2588.
4. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296-300.
5. Osborne CK, Schiff R. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast. 2003;12:362-367.
6. Brodie AM, Njar VC. Aromatase inhibitors and breast cancer. Semin Oncol. 1996;23:10-20.
7. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature Phase III trials. Arimidex Study Group. Cancer. 1998;83:1142-1152.
8. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998;16:453-461.
9. Jonat W, Howell A, Blomqvist C, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer. 1996;32A:404-412.
10. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol. 2001;19:3357-3366.
11. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomized double-blind trial. J Clin Oncol. 2000;18:1399-1411.
12. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Results of two randomized trials designed for combined analysis. Cancer. 2001;92:2247-2258.
13. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21:2101-2109.
14. Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol. 2003;14:1391-1398.
15. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001;12:1527-1532.
16. Smith I, Dowsett M, et al. Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial [abstract 1]. Breast Cancer Res Treat. 2003;82(Suppl 1):S6.
17. Krainick U, Astner A, Jonat W, Wallwiener D. Phase II study to define safety and efficacy of exemestane as preoperative therapy for postmenopausal patients with primary breast cancer-final results of the German Neoadjuvant Aromasin Initiative (GENARI) [abstract 239]. Breast Cancer Res Treat. 2003;82(Suppl. 1):S55.
18. Cataliotti L, Buzdar A, Noguchi S, Bines J. Efficacy of preoperative Arimidex (anastrozole) compared with tamoxifen (PROACT) as neoadjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer [abstract]. Eur J Cancer. 2004;2(Suppl):69.
19. ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131-2139.
20. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081-1092.
21. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793-1802.
22. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002;20:3317-3327.
23. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology Technology Assessment Working Group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol. 2003;21:2597-2599.
24. Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003;21:3357-3365.
25. National Comprehensive Cancer Network. NCCN practice guidelines in oncology: breast cancer. Version 1.2006 [monograph online]. Available from URL: http://www.nccn.org/physician_gls/f_guidelines.html [accessed August 2, 2004].
26. Long BJ, Jelovac D, Handratta V, et al. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J Natl Cancer Inst. 2004;96:456-465.
27. Dowsett M, on behalf of the ATAC Trialists' Group. Analysis of time to recurrence in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial according to estrogen receptor and progesterone receptor status [abstract 4]. Breast Cancer Res Treat. 2003;82(Suppl. 1):S7.
28. Bardou VJ, Arpino G, Elledge RM, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21:1973-1979.
29. Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM. An overview of the pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer. 2002;95:2006-2016.
30. Boccardo F, Rubagotti A, Amoroso D, et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment [abstract 3]. Breast Cancer Res Treat. 2003;82(Suppl. 1):S6-S7.
31. Bajetta E, Martinetti A, Zilembo N, et al. Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism. Ann Oncol. 2002;13:1059-1066.
32. Harper-Wynne C, Ross G, Sacks N, et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev. 2002;11:614-621.
33. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98:1802-1810.
34. U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendation and rationale. Ann Intern Med. 2002;137:526-558.
35. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976;294:405-410.
36. Cuzick J, Buzdar A, Baum M, et al. Adjuvant use of anastrozole in breast cancer. J Clin Oncol. 2004;22:1524-1526.
37. Piccart-Gebhart MJ. New stars in the sky of treatment for early breast cancer. N Engl J Med. 2004;350:1140-1142.